Related Experiment Video

Updated: Sep 3, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K

Dostarlimab: A Review

Bárbara Costa1,2, Nuno Vale1,2,3

  • 1OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.

Biomolecules
|July 27, 2022
PubMed

Insights

Dostarlimab, a PD-1 monoclonal antibody, shows promise in treating mismatch repair deficient (dMMR) cancers. A trial reported a 100% remission rate in rectal cancer, expanding to other solid tumors.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Dostarlimab is a programmed cell death protein 1 (PD-1) monoclonal antibody.
  • It is approved for adult patients with mismatch repair deficient (dMMR), recurrent or advanced endometrial cancer previously treated with a platinum-containing regimen.
  • The initial approval was based on tumor response rate and duration, pending further clinical benefit confirmation.

Purpose of the Study:

  • To review existing knowledge on Dostarlimab.
  • To explore its potential in monotherapy and combination treatments.
  • To highlight emerging applications in other dMMR cancers.

Main Methods:

  • Review of existing literature and clinical trial data.
  • Analysis of Dostarlimab's mechanism of action as a PD-1 inhibitor.
  • Examination of clinical trial results, including NCT04165772.

Main Results:

  • Dostarlimab demonstrated a 100% remission rate in a clinical trial for rectal cancer.
  • This suggests a successful strategy of matching tumor genetics with targeted therapy.
  • The clinical trial is ongoing and enrolling patients with gastric, prostate, and pancreatic cancers.

Conclusions:

  • Dostarlimab is recommended for rectal cancer treatment.
  • The drug's efficacy in dMMR cancers warrants further investigation.
  • Future research should focus on optimizing mono- and combination therapy strategies.
Keywords:
anti-PD-1 antibodyclinical trialsdostarlimabimmunotherapy

More Related Videos

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.2K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
429
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.0K